Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 30, Issue 2, 2008, Pages 149-171

  Moral, M A ^a   Tomillero, A ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ABCIXIMAB; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ADALIMUMAB; AE 941; AMBRISENTAN; AMR 001; ATAZANAVIR; BAY 639044; CCX 282; CEFTOBIPROLE; CERTOLIZUMAB PEGOL; CLOPIDOGREL; DEXVERAPAMIL; EP 7630; FENTANYL; FLUTICASONE FUROATE; FOSPROPOFOL; INCB 18424; KNS 760704; KW 0761; LATANOPROST; MEDI 528; MIDAZOLAM; PEGAPTANIB; PLACEBO; PROTEINASE INHIBITOR; RAPAMYCIN; SITAXSENTAN; TEDUGLUTIDE; TICAGRELOR; TIROFIBAN; TRAVOPROST; TRU 015; UNINDEXED DRUG; UROCORTIN; VANCOMYCIN; VARDENAFIL; VERTEPORFIN; YM 155;

BONE DISEASE; BRONCHITIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; COST EFFECTIVENESS ANALYSIS; EYE DISEASE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; KIDNEY FAILURE; MEDICAL LITERATURE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NUTRITIONAL DISORDER; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE;

CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 44349145047     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Werner, G.S., Ferrari, M., Fritzenwanger, M., Betge, S., Figulsla, H.R. Long-term safety and efficacy of paclitaxel-eluting stents in chronic total coronary occlusions: 3 year follow-up from the paclitaxel in chronic total occlusion (PACTO) study. Eur Heart J 2007, 28(Suppl. 1): 135.
2. Jolly, S., Mehta, S.R., Wallentin, L. et al. The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: Insights from the OASIS 5 trial. Eur Heart J 2007, 28(Suppl. 1): 187.
3. Nakamura, S., Nakamura, S., Bae, J.H. et al. Drug-eluting stents for the treatment of chronic total occlusion: A comparison with Sirolimus, Paclitaxel, Zotarolimus and Tacrolimus-eluting stent. Eur Heart J 2007, 28(Suppl. 1): 577.
4. Grube, E., Dawkins, K.D., Guagliumi, G. et al. TAXUS VI 2-year follow-up: Randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 2007, 28(21): 2578.
5. White, M., Carson, P., Anand, S.I. et al. Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 Arg/Gly receptor polymorphism. Circulation 2007, 116(Suppl. 16): Abst 901.
6. Davis, M.E., Pemberton, C.J., Yandle, T.G. et al. Urocortin 2 infusion in human heart failure. Eur Heart J 2007, 28(21): 2589.
7. Waller, N., Quyyumi, A., Vaughan, D., Moss, T. et al. CD34+CXCR4+ cell therapy (AMR-001) for myocardial infarction: Preliminary processing and product results of a phase I dose escalation study. Blood 2007, 110(11): Abst 773.
8. Valgimigli, M., Bolognese, L., Anselmi, M. et al. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: Design and rationale for the MULTI-STRATEGY trial. Am Heart J 2007, 154(1): 39.
9. Cannon, C.P., Husted, S., Harrington, R.A. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007, 50(19): 1844.
10. Oudiz, J.R. Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension. Chest 2007, 132(Suppl. 4): 474S.
11. Badesch, B.D. Ambrisentan therapy for pulmonary arterial hypertension: A comparison by PAH etiology. Chest 2007, 132(Suppl. 4): 488S.
12. Al-Harbi, A., Helmersen, D., Langleben, D. et al. Multicentered canadian experience with long-term oral sitaxsentan in pulmonary arterial hypertension. Chest 2007, 132(Suppl. 4): 632S.
13. Maul, E., Carrasco, F.G., Costa, V.P. et al. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0,004% to latanoprost 0,005% followed by 6-week, open-label treatment with travoprost 0,004%. Clin Ther 2007, 29(9): 1915.
14. Earnshaw, S.R., Moride, Y., Rochon, S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther 2007, 29(9): 2096.
15. Falkenstein, I.A., Cheng, L., Morrison, V.L. et al. Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina 2007, 27(6): 701.
16. Hinojosa, J., Garcia, S., Bastida, G. et al. Long-tem efficacy of adalimumab treatment in patients with moderately to severely active luminal Crohn's disease who lost response or showed intolerance to infliximab. Am J Gastroenterol 2007 102(Suppl. 2): Abst 1033.
17. Gomollon, F., Hinojosa, J., Nos, P. et al. Long-tem results of adalimumab treatment in subjects with moderately to severely active fistulizing Crohn's disease who have failed response or showed intolerance to infliximab. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 1030.
18. Colombel, J.F., Kamm, M.A., Schwartz, D. et al. Sustainability of adalimumab in fistula healing and response: 2-year data from CHARM and 12-month open-label extension follow-up study. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 1034.
19. Keshav, S., Petryka, R., Vanásk, T. et al. PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 972.
20. Stephens, S., Bloomfield, R., Devine, M.D., Nesbitt, M.A. Efficacy and safety of certolizumab pegol do not appear to be affected by neutralizing antibodies in patients with Crohn's disease. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 971.
21. Tan, S., Feagan, B.G., Schreiber, S., Brown, M.C.J., Gerlier, L.C. Changes in utility scores of patients with active Crohn's disease after certolizumab pegol 400 mg induction and maintenance (PRECISE 2). Am J Gastroenterol 2007, 102(Suppl. 2): Abst 999.
22. Schreiber, S., Panes, J., Mason, D., Lichtenstein, G.R., Sandborn, W.J. Sustained efficacy and tolerability of certolizumab pegol over 18 months: Data from PRECISE 2 and its extension studies (PRECISE 3 and 4). Am J Gastroenterol 2007, 102(Suppl. 2): Abst 960.
23. Feagan, B.G., Coteur, G., Keininger, D.L. Severe Crohn's disease symptoms are relieved by certolizumab pegol. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 959.
24. Vermeire, S., Collin, B., Mitchev, K., Howaldt, S., Hommes, D.W., Rutgeerts, P.J. Compassionate use of certolizumab pegol in patients with Crohn's disease for whom treatment with one or two anti-TNFs failed. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 997.
25. Colombel, J.F., Rutgeerts, P., Sandborn, W.J. et al. Adalimumab safety in Crohn's disease patients: Open-label maintenance following the GAIN and CHARM trials. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 1031.
26. Quigley, M.E., Devane, J., Young, D., Butler, J. A randomized double-blind, placebo-controlled study of R-verapamil in nonconstipated irritable bowel syndrome. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 1046.
27. Gilroy, R., Pehlinov, N., Cyran, J. et al. Efficacy and safety of teduglutide in parenteral nutrition (PN)-dependent SBS subjects: Update of a current multinational trial. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 919.
28. Slatkin, N.E., Rhiner, M., Israel, R.J. Methylnaltrexone (MNTX) for constipation in a patient on opioids with malignant spinal cord compression. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 536.
29. Yen, F.E., Terdiman, P.J., Mahadevan, U. Adalimumab therapy for patients with ulcerative colitis who have lost response or are intolerant of infliximab. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 1035.
30. Kaiser, H.B., Naclerio, R.M., Given, J., Toler, T.N., Ellsworth, A., Philpot, E.E. Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 119(6): 1430.
31. Jimoh, T.B., Guo, R., Ernst, E. Pelargonium sidoides for the treatment of acute bronchitis: A systematic review and meta-analysis. Planta Med 2007, 73(9): Abst 050.
32. Flammer, A., Vo, T.T.N., Ledergerber, B. et al. Effect of atazanovir, compared to other protease inhibitor-containing anti-retroviral therapies, on endothelial function in HIV patients. Eur Heart J 2007, 28(Suppl. 1): 711.
33. Noel, G.J., Strauss, R.S., Amsler, K., Heep, M., Pypstra, R., Solomkin, J.S. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008, 52(1): 37.
34. Corno, E., Camporota, L., Menaldo, E. et al. Blood products requirement in patients treated with drotrecogin alfa (activated) and renal replacement therapy. Intensive Care Med 2007, 33(Suppl. 2): Abst 0589.
35. Gacci, M., Del Popolo, G., Macchiarella, A. et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: Results from a single dose, pilot study. J Urol 2007, 178(5): 2040.
36. Vanderveldt, H.S., Painter, W., Robertson, A., Barkin, J.S. Safety monitoring in a phase 1 first-in-human study of the antiviral agent CMX001: A novel application of wireless capsule endoscopy. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 1156.
37. Rex, D.K., Cohen, L.B. Fospropofol disodium is effective and safe for sedation during colonoscopy. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 396.
38. Ahrens, R.C., England, R.D., Riese, R.J. Inhaled insulin (Exubera): Pulmonary safety profile in pediatric patients with type 1 diabetes. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A194.
39. Krishna, R., Anderson, M.S., Bergman, A.J. et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370(9603): 1907.
40. Rucker, D., Padwal, R., Li, S.K., Curioni, C., Lau, D.C. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ (Clin Res Ed.) 2008, 335(7631): 1194.
41. Addy, C., Wright, H., Van Laere, K. et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008, 7(1): 68.
42. Westhovens, R., Kremer, J., Moreland, L. et al. Maintained efficacy and safety of abatacept in rheumatoid arthritis patients receiving background methotrexate through 5 years of treatment. Arthritis Rheum 2007, 56(Suppl. 9): Abst 950.
43. Ikonomidis, I., Nikolaou, M., Lekakis, J. et al. Inhibition of interleukin-1 activity by anakinra improves endothelial function and coronary flow reserve leading to improved cardiac performance. Eur Heart J 2007, 28(Suppl. 1): 748.
44. Silverman, M.H., Strand, V., Markovits, D. et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: Data from a phase II clinical trial. J Rheumatol 2008, 35(1): 41.
45. Dore, R.K., Hurd, E., Palmer, W. et al. Denosumab increases bone mineral density in patients with rheumatoid arthritis; Twelve-month results. J Bone Miner Res 2007, 22(Suppl. 1): Abst 1208.
46. Burge, D., Chopiak, V., Dvoretskiy, L. et al. TRU-015 improves rheumatoid arthritis disease activity in a randomized, double-blind, placebo-controlled, multi-center phase 2 dose ranging trial. Arthritis Rheum 2007, 56(Suppl. 9): Abst L7.
47. Naumann, L., Feist, E., Natusch, A., Krause, A., Buttgereit, F., Burmester, G. Interleukin-1 receptor antagonist anakinra proves long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0021.
48. Stohl, W., Chatham, W., McKay, J. et al. Progressive normalization of autoantibody, immunoglobulin, and complement levels over 2.5 years of belimumab (fully human monoclonal antibody to BLyS) therapy in systemic lupus erythematosus (SLE) patients. Arthritis Rheum 2007, 56(Suppl. 9): Abst 426.
49. Petri, M., Furie, R., Ginzler, E. et al. Novel combined response endpoint and Systemic Lupus Erythematosus (SLE) Flare Index (SFI) demonstrate belimumab (fully human monoclonal antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years of therapy. Arthritis Rheum 2007, 56(Suppl. 9): Abst 1316.
50. Merrill, J.T., Wallace, D.J., Stohl, W. et al. Safety profile of belimumab (fully human monoclonal antibody to BLyS) in patients with Systemic Lupus Erythematosus (SLE) treated during a placebo-controlled trial and in a long-term continuation study. Arthritis Rheum 2007, 56(Suppl. 9): 427.
51. Lynch, N.O., Earnshaw, S.R., Graham, C.N., Middelhoven, H. Cost-effectiveness of ibandronate injection IV in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates. Osteoporos Int 2007, 18(Suppl. 13): Abst OC24.
52. Lynch, N.O., Earnshaw, S., Graham, C., Patroe, V., Boisdron, J., Middelhoven, H. Ibandronate IV injection is cost-effective in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0325.
53. Diaz-Curiel, M. Serum calcium values after 4 and 24 weeks of treatment with full-length parathyroid hormone PTH(1-84) of postmenopausal women with primary osteoporosis: The first 125 patients. J Bone Miner Res 2007, 22(Suppl. 1): Abst M426.
54. Muche, B., Jobke, B. Semler; Teriparatide treatment following bisphosphonate-resistent osteoporosis: 6 months clinical data of the BBB-study. J Bone Miner Res 2007, 22(Suppl. 1): Abst T372.
55. Briot, K., Ravaud, P., Liu-Leage, S., Roux, C. Improvement of the persistence with teriparatide in postmenopausal osteoporosis: The French experience of an education program. J Bone Miner Res 2007, 22(Suppl. 1): Abst M441.
56. Eastell, R., McCloskey, E.V., Glover, S. et al. Rapid and robust biochemical response to teriparatide therapy for osteoporosis. J Bone Miner Res 2007, 22(Suppl. 1): Abst T366.
57. Cosman, F., Wermers, R.A., Recknor, C. et al. Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. J Bone Miner Res 2007, 22(Suppl. 1): Abst S423.
58. Pelletier, J.P., Raynauld, J.P., Bias, P. et al. Licofelone, a 5-lip-oxygenase and cyclooxygenase inhibitor, reduces the progression of knee osteoarthritis (OA): A double blind, multicenter two-year study using quantitative MRI. Osteoporos Int 2007, 18(Suppl. 13): Abst OC36.
59. Laine, L., Curtis, S.P., Langman, M. et al. Lower GI clinical events in a double-blind randomized comparison of a COX-2 selective inhibitor (etoricoxib) and a traditional NSAID (diclofenac) in 34,701 arthritis patients. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0238.
60. Cosman, J.W.N., Zion, M., Dempster, D.W., Lindsay, R. Reduction in serum 25(OH)D during PTH treatment. J Bone Miner Res 2007, 22(Suppl. 1): Abst T373.
61. Hadji, P., Nickelsen, T., Marin, F. et al. Bone mineral density response to 2 years of continuous treatment with teriparatide: Final results from the EUROFORS study. Osteoporos Int 2007, 18(Suppl. 13): Abst OC15.
62. Reginster, J.Y., Brixen, K., Cormier, C., Cannata, J. Strontium ranelate demonstrates vertebral and non-vertebral ANTI fracture efficacy including hip fractures over 5 years in postmenopausal osteoporotic women. Osteoporos Int 2007, 18(Suppl. 13): Abst OC42.
63. Hue, T.F., Bilezikian, J.P., Ensrud, K.E. et al. Year 3 effects on bone mass in women using bisphosphonates after PTH therapy: Follow-up results from the PaTH II study. J Bone Miner Res 2007, 22(Suppl. 1): Abst 1094.
64. Boivin, G., Meunier, P.J. After three years of treatment with strontium ranelate 2 g per day bone strontium content reaches a plateau. Osteoporos Int 2007, 18(Suppl. 13): Abst P302.
65. Li, J., Burr, D.B., Stepan, J.J. et al. Teriparatide improves bone microarchitecture in postmenopausal women previously treated with alendronate. J Bone Miner Res 2007, 22(Suppl. 1): Abst 1095.
66. Borggrefe, J., Graeff, C., Nickelsen, T.N. et al. Effects of 2 year teriparatide treatment on 3-D femoral neck bone distribution, geometry and bone strength: Results from the EUROFORS study. J Bone Miner Res 2007, 22(Suppl. 1): Abst 1269.
67. Reidy, D.L., Chung, K.Y., Timoney, J.P. et al. Bevacizumab 5 mg/kg can be safely infused over 10 minutes. J Clin Oncol 2007, 25(18, Suppl.): Abst 4135.
68. Nakagawa, K., Satoh, T., Okamoto, I. et al. Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan. J Clin Oncol 2007, 25(18, Suppl.): Abst 3536.
69. Fiveash, J.B., Nabors, L.B., Raizer, J.J., Avgeropoulos, N., Modarresifar, H., Shen, S. Tumor specific targeting of intravenous 1311-chlorotoxin (TM-601) in patients with recurrent glioma. Int J Radiat Oncol Biol Phys 2007, 69(3, Suppl.): Abst 2097.
70. Miller, K., Wang, M., Gralow, J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med 2007, 357(26): 2666.
71. Schmiegel, W.H., Reinacher-Schick, A., Freier, W. et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (Cap0x/Bev) versus capecitabine/irinotecan (Caplri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. J Clin Oncol 2007, 25(18, Suppl.): Abst 4034.
72. DePrimo, S.E., Harmon, C., Saltz, L.B. et al. Variations in circulating levels of VEGF and sVEGFR-2, sVEGFR-3 and sKIT in metastatic CRC patients treated with sunitinib after failure of prior chemotherapy with or without bevacizumab. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst LB-361.
73. Remák, E., Mullins, C.D., Akobundu, E., Charbonneau, C., Woodruff, K. Economic evaluations of sunitinib versus interferon-alfa (IFN-alpha) in first-line metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007, 25(18, Suppl.): Abst 6607.
74. Lu, C., Lee, J.J., Komaki, R. et al. A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303). J Clin Oncol 2007, 25(18, Suppl.): Abst 7527.
75. Gittelman, M., Pommerville, P.J., Persson, B.E., Olesen, T.K. A multicentre, randomised one year dose-finding study of degarelix, a gonadotropin-releasing hormone (GnRH) receptor blocker, in prostate cancer patients. Urology 2007, 70(Suppl. 3A): Abst MP-08.21.
76. Stall, B., Citrin, D., Seidel, G. et al. Early results of a pilot study of intra-tumoral Injection of TNFerade(TM) biologic concurrent with neoadjuvant chemoradiation therapy for the treatment of primary and recurrent rectal cancer. Int J Radiat Oncol Biol Phys 2007, 69(3, Suppl.): Abst 2185.
77. Chu, Q.S., Forouzesh, B., Syed, S. et al. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007, 25(4): 359.
78. Wei, Q., Levens, E.D., Nieman, L.K. CDB-2914, a novel selective progesterone receptor modulator, differentially regulates endometrial gene expression in the proliferative phase of the menstrual cycle. Fertil Steril 2007, 88(Suppl. 1): Abst P-259.
79. Levens, E.D., Wei, Q., Nieman, L.K. Indian hedgehog and its associated down-stream targets are altered in response to in vivo CDB-2914 administration. Fertil Steril 2007, 88(Suppl. 1): Abst P-265.
80. Liedtke, M., Twist, C., Bieber, M. et al. A phase I study of a novel human monoclonal antibody (mAb216) with chemotherapy for the treatment of patients with relapsed or refractory B-lineage acute lymphoblastic leukemia. Blood 2007, 110(11): Abst 2831.
81. Kantarjian, H.M., Giles, F., Gattermann, N. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110(10): 3540.
82. Lum, G.L., Uberti, P.J., Al-Kadhimi, Z. et al. Phase I trial of multiple infusions of autologous activated T cells with anti-CD3 x anti-CD20 bispecific antibody (CD20Bi) after autologous peripheral blood stem cell transplant for non-Hodgkins lymphoma to improve graft-vs-lymphoma effects. Blood 2007, 110(11): Abst 4488.
83. Hagenbeek, A., Bischof-Delaloye, A., Radford, A.J. et al. 90Y-Ibritumomab tiuxetan (Zevalin) consolidation of first remission in advanced stage follicular non-Hodgkin s lymphoma: First results of the international randomized phase 3 First-line Indolent Trial (FIT) in 414 patients. Blood 2007, 110(11): Abst 643.
84. D' Amore, F., Radford, J., Jerkeman, M. et al. Zanolimumab (HuMax-CD4TM), a fully human monoclonal antibody: Efficacy and safety in patients with relapsed or treatment-refractory noncutaneous CD4+ T-cell lymphoma. Blood 2007, 110(11): Abst 3409.
85. Uike, N., Tsukasaki, K., Utsunomiya, A. et al. Phase I study of KW-0761, a humanized anti-CCR4 antibody, in patients (pts) with relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL): Preliminary results. Blood 2007, 110(11): Abst 4492.
86. Alsina, M., Trudel, S., Vallone, M. et al. Phase I single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood 2007, 110(11): Abst 411.
87. Richardson, P.G., Sonneveld, P., Schuster, M. et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 2007, 110(10): 3557.
88. Verstovsek, S., Kantarjian, H., Pardanani, A. et al. INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Blood 2007, 110(11): Abst 558.
89. Drory, V., Artmonov, I., Nefussy, B. Evaluation of treatment with rasagiline in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007, 8(Suppl. 1): Abst P129.
90. Mintzer, J.E., Tune, L.E., Breder, C.D. et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 2007, 15(11): 918.
91. Otoul, C., Von Rosenstiel, P., Stockis, A. Evaluation of the pharmacokinetic interaction of brivaracetam on other anti-epileptic drugs in adults with partial-onset seizures. Epilepsia 2007, 48(Suppl. 6): Abst 3.232.
92. Brodsky, A., Costantini, C., Von Rosenstiel, P. Safety and tolerability of brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 2007, 48(Suppl. 6): Abst 3.256.
93. Faught, R.E., Rosenfeld, W.E., Holmes, G.L. et al. A double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and tolerability of carisbamate (RWJ-333369) as adjunctive therapy in patients with refractory partial seizures. Epilepsia 2007, 48(Suppl. 6): Abst 3.221.
94. Chung, S.S., Sperling, M., Biton, V. et al. Efficacy and safety as oral adjunctive treatment for partial-onset seizures. Epilepsia 2007, 48(Suppl. 6): Abst 3.197.
95. Mansbach, H., Li, Y. Double-blind, placebo-controlled trial of retigabine as adjunctive therapy in partial-onset seizures: Gender subset analysis. Epilepsia 2007, 48(Suppl. 6): Abst 3.245.
96. Alonso-Navarro, H., Fernandez-Diaz, A., Martin-Prieto, M. et al. Tremor associated to chronic inflammatory demyelinating peripheral neuropathy (CIDP): Treatment with pregabalin. Mov Disord 2007, 22(Suppl. 16): Abst 965.
97. Dispenzieri, A., Klein, C.J., Mauermann, M.L. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007, 110(3): 1075.
98. Jackson, C., Gronseth, G., Rosenfeld, J. et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type B (BTXB) for sialorrhea in ALS. Amyotroph Lateral Scler 2007, 8(Suppl. 1): Abst C94.
99. Feltner, D., Wittchen, H.U., Kavoussi, R. et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008, 23(1): 18.
100. Septien-Velez, L., Pitrosky, B., Padmanabhan, S.K., Germain, J.M., Tourian, K.A. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007, 22(6): 338.
101. Feighner, J.P., Sverdlov, L., Hlavka, J. et al. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients. Int Clin Psychopharmacol 2008, 23(1): 29.
102. Badalyan, R.R., Fanarjyan, S.V., Aghajanyan, I.G. Pilot randomized efficacy and tolerability study of duloxetine 30 mg in patients with premature ejaculation. J Urol 2007, 177(4, Suppl.): Abst 1167.
103. Al-Kandari, A.M., Shaaban, H.H., Ibrahim, H.M., Elshebiny, Y.H., Shokeir, A.A. A prospective clinical trial using prilocainelidocaine cream to treat premature ejaculation: Excellent outcome. J Urol 2007, 177(4, Suppl.): Abst 1165.
104. Lane, H.Y., Liu, Y.C., Huang, C.L. et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study. Biol Psychiatry 2008, 63(1): 9.
105. Muller, J.E., Wentzel, I., Koen, L., Niehaus, D.J., Seedat, S., Stein, D.J. Escitalopram in the treatment of multisomatoform disorder: A double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2008, 23(1): 43.
106. Laschke, S., Carl, S. Detrusor overactivity after prostate resection: Preventing postoperative incontinence with darifenacin. Urology 2007, 70(Suppl. 3A): Abst POS-02.74.
107. Yajima, A., Takahashi, H.E., Akizawa, T. Impact of cinacalcet HCl on bone remodeling and minimodeling in patients with secondary hyperparathyroidism. J Bone Miner Res 2007, 22(Suppl. 1): Abst T495.
108. Chapple, C.R., Drogendijk, T., Wright, D.M., Bolodeoku, J. Responses to solifenacin in overactive bladder patients with or without incontinence ('OAB wet' and 'OAB dry'): Post-hoc results from the randomised, double-blind STAR study. Urology 2007, 70(Suppl. 3A): Abst MP-10.16.
109. Zinner, N., Chancellor, M.B., Forero-Schwanhaeuser, S. Diary and patient-reported outcomes with solifenacin in patients with overactive bladder reporting high symptom bother and residual urgency on tolterodine. Urology 2007, 70(Suppl. 3A): Abst POS-01.132.
110. Gleicher, N., Barad, D. The impact of dehydroepiandrosterone (DHEA) supplementation on IVF pregnancy rates in women ages 40-47 years. Fertil Steril 2007, 88(Suppl. 1): Abst P-567.
111. Pinkerton, J.V., Utian, W.H., Archer, D.F., Levine, A., Chines, A.A., Constantine, G. Endometrial and ovarian safety of bazedoxifene (BZA) in the prevention of postmenopausal osteoporosis. Fertil Steril 2007, 88(Suppl. 1): Abst P-407.
112. Von Muhlen, D., Bergstrom, J., Kritz-Silverstein, D. The effect of DHEA supplements on bone and body composition: The DAWN study. Osteoporos Int 2007, 18(Suppl. 13): Abst P258.
113. Cha, G.S., Yoo, T.K., Jo, M.K., Kim, H.S. Effects of dutasteride on the microvessel density of the prostate in BPH patients. Urology 2007, 70(Suppl. 3A): Abst MP-20.19.
114. O' Byrne, P., Boulet, L.P., Gawreau, G. et al. A single dose of MEDI-528, a monoclonal antibody against interleukin-9, is well tolerated in mild and moderate asthmatics in the phase II trial MI-CP-138. Chest 2007, 132(4, Suppl.): 478S.
115. Wenzel, S., Wilbraham, D., Fuller, R., Getz, E.B., Longphre, M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet 2007, 370(9596): 1422.
116. Brunasso, A.M.G., Pimpinelli, N. Recalcitrant generalized pustular psoriasis associated to dactilitis successfully treated with infliximab. J Eur Acad Dermatol Venereol 2007, 21 (Suppl. 1): Abst P 005.
117. Laffitte, E., Gugerli, O., Keta, A., Rothuizen, L., Dudler, J., Panizzon, R.G. Severe inflammatory psoriasis flare during efalizumab therapy. J Eur Acad Dermatol Venereol 2007, 21(Suppl. 1): Abst P 106.
118. Lopeztello, A., Juarez, L.I. An experience with efalizumab in psoriasis patients in the medical center ISSEMYM. J Eur Acad Dermatol Venereol 2007, 21 (Suppl. 1): Abst P 104.
119. Jautova, J., Kampe, T., Baloghova, J., Ficova, M. The psoriasis vulgaris with efalizumab - Our experiences. J Eur Acad Dermatol Venereol 2007, 21 (Suppl. 1): Abst P 092.
120. Solovan, C., Ciolan, M. Factors influencing the outcome of the treatment with efalizumab for psoriasis. J Eur Acad Dermatol Venereol 2007, 21(Suppl. 1): Abst P 081.
121. Unanue, J. Treatment of psoriasis by efaluzimab: A report on ten cases. J Eur Acad Dermatol Venereol 2007, 21(Suppl. 1): Abst P 095.
122. Huestis, M.A., Boyd, S.J., Heishman, S.J. et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berlin) 2007, 194(4): 505.
123. Rennard, S.I., Jorenby, D.E., Gonzales, D. et al. A randomized placebo-controlled trial of a conjugate nicotine vaccine (Nic-VAX(R)) in smokers who want to quit: 12 month results. Circulation 2007, 116(16, Suppl.): Abst 3712.
124. Lassen, R.M., Dahl, E.O., Mismetti, P., Destrée, D. AVE5026, a new anticoagulant for the prevention of venous thromboembolism in total knee replacement surgery TREK: A dose ranging study. Blood 2007, 110(11): Abst 311.
125. Ethgen, D., Phillips, J., Baidoo, C. et al. Dose-dependent increases in endogenous parathyroid hormone concentrations after administration of a calcium sensing receptor antagonist to normal volunteers: Potential for an oral bone forming agent. J Bone Miner Res 2007, 22(Suppl. 1): Abst 1131.
126. Wensing, G., Haase, C., Brendel, E., Böttcher, M.F. Pupillography as a sensitive, noninvasive biomarker in healthy volunteers: First-in-man study of BAY 63-9044, a new 5-HT1A-receptor agonist with dopamine agonistic properties. Eur J Clin Pharmacol 2007, 63(12): 1123.
127. Ragueneau-Majlessi, I., Levy, R., Solanki, B., Zannikos, P., Novak, G. Pharmacokinetics, safety, and tolerability of the new anti-epileptic drug carisbamate (RWJ-333369) in elderly adults. Epilepsia 2007, 48(Suppl. 6): Abst 3.211.
128. Ceglia, L., Harris, S.S., Rasmussen, H., Dawson-Hughes, B. Activation of the calcium sensing receptor with cinacalcet increases serum gastrin levels in healthy older subjects. J Bone Miner Res 2007, 22(Suppl. 1): Abst M221.
129. Wu, J., Vakily, M., Witt, G., Mulford, D. TAK-390MR vs. lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher%-time pH>4. Am J Gastroenterol 2007, 102(Suppl. 2): Abst 15.
130. Reisinger, K.S., Block, S.L., Lazcano-Ponce, E. et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: A randomized controlled trial. Pediatr Infect Dis J 2007, 26(3): 201.
131. Hallschmid, M., Jauch-Chara, K., Born, J., Kern, W. Reduction of food intake by insulin detemir in comparison to regular human insulin. Exp Clin Endocrinol Diabetes 2007, 115(8): Abst.
132. Snape, D.M., Perrett, P.K., Ford, J.K. et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: A randomized controlled trial. JAMA - J Am Med Assoc 2008, 299(2): 173.
133. Goepfert, P.A., Tomaras, G.D., Horton, H. et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multiprotein recombinant vaccine in uninfected human volunteers. Vaccine 2007, 25(3): 510.
134. Graham, C.F., Mather, J.L., Ingersoll, E. et al. Preliminary safety and pharmacokinetic results following administration of ascending single doses of KNS-760704 to healthy volunteers. Amyotroph Lateral Scler 2007, 8(Suppl. 1): Abst SW303.
135. Aponte, J.J., Aide, P., Renom, M. et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: A double blind randomised controlled phase I/IIb trial. Lancet 2007, 370(9598): 1543.